

In the claims:

1-95. (Cancelled).

96. (Currently Amended) A method of killing a ~~specific target~~malignant glioma cell and/or tissue, the method comprising exposing the ~~specific target~~malignant glioma cell and/or tissue to a composition-of-matter comprising:

(i) a double stranded RNA molecule, said molecule consisting of 2 RNA strands which induces viral-like double stranded RNA mediated apoptosis, triggered by up-regulation of interferon (IFN)- α - β expression in said cell and/or tissue;

(ii) a nucleic acid carrier comprising polyethylenimine (PEI); and

(iii) a targeting moiety comprising epidermal growth factor (EGF), said ~~targeting moiety being a ligand or antibody which binds to a cell surface marker being specific to the target cell and/or tissue~~;

wherein,

said double stranded RNA molecule is associated with said nucleic acid carrier, said nucleic acid carrier is associated with said targeting moiety and said targeting moiety is not covalently bound to said double stranded RNA molecule,

and further wherein said double stranded RNA, said targeting moiety and said nucleic acid carrier form a particle which penetrates solid tumor tissue, thereby killing the ~~specific target cell and/or tissue~~ malignant glioma.

97. (Currently Amended) The method of claim 96, wherein said exposing the ~~specific target cell and/or tissue~~ malignant glioma to said composition-of-matter is effected by administering said composition-of-matter to a vertebrate subject bearing the ~~specific target cell and/or tissue~~ malignant glioma.

98. (Previously Presented) The method of claim 97, wherein said administering said composition-of-matter to said vertebrate subject is effected by administering said composition-of-matter to said subject systemically and/or to a central nervous system location of said vertebrate subject.

99. (Previously Presented) The method of claim 96, wherein said composition of matter further comprises melittin.

100. – 106. (Cancelled).

107. (Previously Presented) The method of claim 96, wherein said double stranded RNA molecule comprises a polyinosinic acid strand and/or a polycytidylic acid strand.

108. (Currently Amended) The method of claim 96, wherein said nucleic acid carrier further comprises poly(ethylene glycol)~~a polymer selected from the group consisting of a polycationic polymer, a non-ionic water soluble polymer, a polyether polymer and a biocompatible polymer.~~

109. (Cancelled)

110. (Previously Presented) The method of claim 96, wherein said double stranded RNA molecule is wholly composed of matching ribonucleotide pairs.

111. (Previously Presented) The method of claim 96, wherein said double stranded RNA molecule comprises mismatched ribonucleotide pairs on average less than one base pair in every 29 consecutive base residues.

112. (Previously Presented) The method of claim 99, wherein a ratio of said double stranded RNA molecule: said nucleic acid carrier: said melittin is selected such that at a concentration of 10 µg/ml the composition is capable of selectively killing more than 95 % of glioblastoma cells 24 hours following transfection as measured in an in vitro assay.

113. (Previously Presented) The method of claim 96, wherein said carrier is covalently associated with said targeting moiety.

114. (Cancelled)

115. (New) The method of claim 96, wherein said malignant glioma is a glioblastoma.